CD44v6与非小细胞肺癌的研究进展

doi:10.11904/j.issn.1002-3070.2016.02.017

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (2): 172-175.doi: 10.11904/j.issn.1002-3070.2016.02.017

CD44v6与非小细胞肺癌的研究进展

陈明慧, 陈喜杰综述, 王艳审校

哈尔滨医科大学附属肿瘤医院呼吸内科(哈尔滨 150086)

收稿日期:2016-01-05 出版日期:2016-04-28 发布日期:2016-04-28
通讯作者: 王艳,E-mail:wangyan86298263@163.com
作者简介:陈明慧,女,(1989-),硕士研究生,从事肺癌治疗的研究

Research progress of CD44v6 in non-small cell lung cancer

CHEN Minghui, CHEN Xijie, WANG Yan

Department of Respiratory Medicine,The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081,China

Received:2016-01-05 Online:2016-04-28 Published:2016-04-28

摘要/Abstract

摘要： CD44是一种跨膜糖蛋白,是由单一基因所编码的具有高度特异性的单链膜表面糖蛋白家族。其主要参与细胞与细胞、细胞与基质之间的特异性黏附过程。CD44v6是CD44家族的成员之一,其与非小细胞肺癌转移和预后的相关性成为近几年来研究的一大热点,本文就当前CD44v6与非小细胞肺癌的研究进展做一综述。

关键词: CD44v6, 非小细胞肺癌, 文献分析

Abstract: CD44 is a transmembrane glycoprotein,which is a family of highly specific single chain membrane surface glycoproteins by a single gene.CD44 is mainly involved in the specific adhesion between cells and cells,cells and matrix.CD44v6 is a member of the CD44 family,and its correlation with metastasis and prognosis of non small cell lung cancer(NSCLC)has become a hot research topic in recent years.The current research progress of CD44v6 and NSCLC are reviewed in this paper.

Key words: CD44v6, Non-small cell lung cancer, Literature review

中图分类号:

R734.2

陈明慧, 陈喜杰综述, 王艳审校. CD44v6与非小细胞肺癌的研究进展[J]. 实用肿瘤学杂志, 2016, 30(2): 172-175.

CHEN Minghui, CHEN Xijie, WANG Yan. Research progress of CD44v6 in non-small cell lung cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 172-175.

参考文献

1 Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30.
2 Haynes BF,Telen MJ,Hale LP,et al.CD44-a molecule involved in leukocyte adherence and T-cell activation[J].Immunology Today,1989,10(12):423-428.
3 Orian-Rousseau V,Sleeman J.CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals[J].Adv Cancer Res,2014,123(2):231-54.
4 Orian-Rousseau V.CD44,a therapeutic target for metastasising tumours[J].European Journal of Cancer,2010,46(7):1271-1277.
5 Almond A.Hyaluronan[J].Cell Mol Life Sci,2007,64(13):1591-1596.
6 Bourguignon LYW,Spevak CC,Wong G,et al.Hyaluronan-CD44 interaction with protein kinase C promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21,leading to down-regulation of the tumor suppressor protein PDCD4,anti-apoptosis,and chemotherapy resistance in breast tumor cells[J].Journal of Biological Chemistry,2009,284(39):26533-26546.
7 Negi LM,Talegaonkar S,Jaggi M,et al.Role of CD44 in tumour progression and strategies for targeting[J].Journal of Drug Targeting,2012,20(7):561-573.
8 孙冰生,裴宝祥,王安雷,等.骨桥蛋白及其受体 CD44v 对肿瘤侵袭调控的研究进展[J].中国肺癌杂志,2015,18(11):714-717.
9 李轰,祝凯,魏朝霞,等.非小细胞肺癌 CD44 途径免疫逃逸机制初步探讨[J].齐鲁医学杂志,2010,25(3):202-204.
10 杨景伟,沈毅,魏煜程,等.CD44s 和 CD44v6 在肺癌组织中的表达及意义[J].山东医药,2007,46(36):51-52.
11 Situ D,Long H,Lin P,et al.Expression and prognostic relevance of CD44v6 in stage I non-small cell lung carcinoma[J].J Cancer Res Clin Oncol,2010,136(8):1213-1219.
12 牛艳清.NSCLC中COX-2和CD44v6的表达与淋巴结转移关系[J].长治医学院学报,2014,28(3):178-180.
13 Su CY,Li YS,Han Y,et al.Correlation between expression of cell adhesion molecules CD44v6 and E-cadherin and lymphatic metastasis in non-small cell lung cancer[J].Asian Pac J Cancer Prev,2013,15(5):2221-2224.
14 Afify AM,Tate S,Durbin-Johnson B,et al.Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors[J].The International Journal of Biological Markers,2010,26(1):50-57.
15 Luo Z,Wu RR,Lv L,et al.Prognostic value of CD44 expression in non-small cell lung cancer:a systematic review[J].Int J Clin Exp Pathol,2014,7(7):3632-3646.
16 Hirata T,Fukuse T,Naiki H,et al.Expression of CD44 variant exon 6 in stage I non-small cell lung carcinoma as a prognostic factor[J].Cancer Research,1998,58(6):1108-1110.
17 Zhao S,He JL,Qiu ZX,et al.Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer:a meta-analysis.[J].Asian Pacific Journal of Cancer Prevention,2014,15(16):6761-6766.
18 Ramasami S,Kerr KM,Chapman AD,et al.Expression of CD44v6 but not E-cadherin or β-catenin influences prognosis in primary pulmonary adenocarcinoma[J].The Journal of Pathology,2000,192(4):427-432.
19 Ko YH,Won HS,Jeon EK,et al.Prognostic significance of CD44s expression in resected non-small cell lung cancer[J].Bmc Cancer,2011,11(1):1-9.
20 Jiang H,Zhao W,Shao W.Prognostic value of CD44 and CD44v6 expression in patients with non-small cell lung cancer:meta-analysis[J].Tumour Biol,2014,35(8):7383-7389.
21 Li R,Zhang C,Wang B.A study on the change of the serum levels of soluble sCD44v6 and the expression of CD44v6 in the tissues of gastric tumor[J].Hebei Med J,2006,28(5):355-358.
22 He Y,Zhang J,Wang SK,et al.Serum sCD44v6 and sE-cadherin levels in patients with esophageal squamous cell carcinoma[J].Zhejiang Da Xue Xue Bao,2012,41(3):305-309.
23 赵丽红,田建辉.非小细胞肺癌患者 sCD44v6 的检测意义[J].实用中西医结合临床,2006,6(5):11-12.
24 李炯,沈德义,沈敏祺.sCD44V6 检测对非小细胞肺癌的临床意义[J].肿瘤研究与临床,2005,17(1):21-22.
25 叶珩,钱科卿,岑玲.非小细胞肺癌患者血清 sCD44v6 检测的临床意义[J].现代肿瘤医学,2008,16(1):46-47.
26 张真,韩淑红,张小涛,等.非小细胞肺癌同步放化疗前后血清 CD44v6 表达水平及其临床意义[J].医学研究杂志,2013,42(7):112-114.

[1]	卢菊萍, 胡军, 邓永明, 廖淑芳. 下调FKBP4通过阻断PI3K/Akt/mTOR信号通路抑制非小细胞肺癌的恶性进展[J]. 实用肿瘤学杂志, 2025, 39(3): 184-190.
[2]	李才正, 郑婧, 苏巧俐. 不可切除局部晚期非小细胞肺癌免疫治疗进展[J]. 实用肿瘤学杂志, 2025, 39(1): 67-72.
[3]	郝慧婷, 赵惠娟, 徐巧慧. 癌症高甲基化1在非小细胞肺癌中的表达及其临床意义[J]. 实用肿瘤学杂志, 2024, 38(5): 306-312.
[4]	徐灵燕, 李倩妮, 李健, 姚雪佩, 刘美娜. 非小细胞肺癌患者首次住院天数对治疗质量的影响分析[J]. 实用肿瘤学杂志, 2024, 38(4): 221-226.
[5]	姚雪佩, 白山奇, 刘美娜. 基于因果图模型的非小细胞肺癌治疗质量影响因素分析[J]. 实用肿瘤学杂志, 2024, 38(4): 227-234.
[6]	李健, 李倩妮, 徐灵燕, 姚雪佩, 刘美娜. 基于双重稳健估计方法的非小细胞肺癌治疗过程对院内死亡的因果效应研究[J]. 实用肿瘤学杂志, 2024, 38(4): 235-240.
[7]	程泳铭, 董欢欢, 徐晖. Hsa-let-7b-5p抑制非小细胞肺癌的增殖、迁移和侵袭[J]. 实用肿瘤学杂志, 2024, 38(3): 157-167.
[8]	张萱, 李欣, 赵康. 血清炎性标志物与一线免疫抑制剂治疗晚期非小细胞肺癌患者预后的关系[J]. 实用肿瘤学杂志, 2024, 38(1): 37-44.
[9]	苗玲, 赵之寒, 王敏. 非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义[J]. 实用肿瘤学杂志, 2023, 37(4): 344-350.
[10]	曹莹月, 庞露薏, 张键, 金时. 癌相关成纤维细胞在非小细胞肺癌进展中的作用[J]. 实用肿瘤学杂志, 2023, 37(4): 383-388.
[11]	陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.
[12]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[13]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[14]	朱开彬, 贺长军, 陈澜涛, 孔祥龙, 赵苏, 徐世东. TAM通过PLGF/Flt-1和TGF-β1通路促进非小细胞肺癌生长和肿瘤血管异生的研究[J]. 实用肿瘤学杂志, 2022, 36(5): 391-397.
[15]	刘倩倩, 尚利华. 晚期非小细胞肺癌免疫治疗相关不良反应与疗效的相关性研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 463-467.

CD44v6与非小细胞肺癌的研究进展

Research progress of CD44v6 in non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价